标题
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
作者
关键词
-
出版物
Frontiers in Neurology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-07-16
DOI
10.3389/fneur.2020.00634
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review
- (2019) Hiroko Kadota et al. Current Rheumatology Reports
- Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma
- (2019) Nora Möhn et al. MELANOMA RESEARCH
- Neurotoxicity associated with cancer immunotherapy
- (2019) Claire Perrinjaquet et al. CURRENT OPINION IN NEUROLOGY
- Cardiovascular toxicities associated with immune checkpoint inhibitors
- (2019) Jiun-Ruey Hu et al. CARDIOVASCULAR RESEARCH
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
- (2019) Douglas B. Johnson et al. Journal for ImmunoTherapy of Cancer
- Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
- (2019) Anne Zaremba et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy
- (2019) Asako Onda et al. INTERNAL MEDICINE
- Myasthenia Gravis Induced by Immune Checkpoint Inhibitors
- (2019) Ondine Becquart et al. JOURNAL OF IMMUNOTHERAPY
- Diaphragm involvement in immune checkpoint inhibitor‐related myositis
- (2019) Kenji Sekiguchi et al. MUSCLE & NERVE
- Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report
- (2019) Hikaru Kamo et al. BMC Neurology
- Immune checkpoint inhibitors‐induced neuromuscular toxicity: from pathogenesis to treatment
- (2019) Dimitri Psimaras et al. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
- Trouble at the junction: When myopathy and myasthenia overlap
- (2019) Stefan Nicolau et al. MUSCLE & NERVE
- Myasthenia gravis induced by avelumab
- (2019) Carlen Yuen et al. Immunotherapy
- Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation
- (2019) Rafael Valenti-Azcarate et al. NEUROMUSCULAR DISORDERS
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature
- (2019) Houssein Safa et al. Journal for ImmunoTherapy of Cancer
- Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related adverse reactions in the nervous system
- (2019) Jiayu Shi et al. Thoracic Cancer
- Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management
- (2018) Kylie H. Kang et al. AMERICAN JOURNAL OF OTOLARYNGOLOGY
- Relapsed Myasthenia Gravis after Nivolumab Treatment
- (2018) Ayumi Mitsune et al. INTERNAL MEDICINE
- Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
- (2018) So-Young Huh et al. Journal of Clinical Neurology
- Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
- (2018) Vera Montes et al. Frontiers in Neurology
- Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
- (2018) Justin C. Kao et al. Current Neurology and Neuroscience Reports
- Rituximab in the treatment of pembrolizumab-induced myasthenia gravis
- (2018) S.M. Crusz et al. EUROPEAN JOURNAL OF CANCER
- Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis
- (2018) Mohanad Algaeed et al. NEUROLOGY
- Clinical spectrum of neuromuscular complications after immune checkpoint inhibition
- (2018) Araya Puwanant et al. NEUROMUSCULAR DISORDERS
- Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
- (2017) D. Makarious et al. EUROPEAN JOURNAL OF CANCER
- Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
- (2017) S. Cuzzubbo et al. EUROPEAN JOURNAL OF CANCER
- Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review
- (2017) Yoshikazu Hasegawa et al. Immunotherapy
- Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder
- (2017) Elaine Chang et al. JOURNAL OF IMMUNOTHERAPY
- Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis
- (2017) Ryan Ying Cong Tan et al. Journal of Thoracic Oncology
- Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma
- (2017) Yu-Hsiu Chen et al. MEDICINE
- Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer
- (2017) Jia-Hung Chen et al. MEDICINE
- Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients
- (2017) Bella H.V. Nguyen et al. MELANOMA RESEARCH
- A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma
- (2017) Iyad Alnahhas et al. MUSCLE & NERVE
- Refractory myasthenia gravis exacerbation triggered By pembrolizumab
- (2017) Damien E. Earl et al. MUSCLE & NERVE
- Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
- (2017) Natalia L. Gonzalez et al. NEUROMUSCULAR DISORDERS
- Pembrolizumab-induced myasthenia gravis: A fatal case report
- (2017) Katherine L March et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Myasthenic crisis and polymyositis induced by one dose of nivolumab
- (2016) Toshihiro Kimura et al. CANCER SCIENCE
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
- (2016) Lisa Zimmer et al. EUROPEAN JOURNAL OF CANCER
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Benign form of myasthenia gravis after nivolumab treatment
- (2016) Giorgia Sciacca et al. MUSCLE & NERVE
- Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer
- (2016) Pinar Polat et al. MUSCLE & NERVE
- Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
- (2016) K. H. Vincent Lau et al. MUSCLE & NERVE
- Myasthenia gravis exacerbation associated with pembrolizumab
- (2016) Julia Zhu et al. MUSCLE & NERVE
- Complicating autoimmune diseases in myasthenia gravis: a review
- (2015) Aliona Nacu et al. AUTOIMMUNITY
- Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma
- (2015) Takushi Shirai et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer
- (2015) Aaron I. Loochtan et al. MUSCLE & NERVE
- The autoimmune spectrum of myasthenia gravis: a Swedish population-based study
- (2014) F. Fang et al. JOURNAL OF INTERNAL MEDICINE
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Muscle autoantibodies in myasthenia gravis: beyond diagnosis?
- (2012) Matthew N Meriggioli et al. Expert Review of Clinical Immunology
- Evaluation of Neuromuscular Junction Disorders in the Electromyography Laboratory
- (2012) Vern C. Juel NEUROLOGIC CLINICS
- Associated autoimmune diseases in myasthenia gravis A population-based study
- (2010) P. B Christensen et al. ACTA NEUROLOGICA SCANDINAVICA
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
- (2009) Matthew N Meriggioli et al. LANCET NEUROLOGY
- Lifetime course of myasthenia gravis
- (2007) David Grob et al. MUSCLE & NERVE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More